Publicacions
-
Krauel L, Pasten A, Gorostegui M, Mañé S, Martin Giménez MP, Coronas-Soucheiron M, Carrasco-Torrents R and Mora J.
Use of Radioguided Surgery for Small and Difficult-to-Locate Relapsed MIBG (+) High-Risk Neuroblastoma Lesions.
Cancers . 16(19): .
-
Mahnoor S, Molnar C, Velázquez D, Reina J, Llamazares S, Heinen JP, Mora J and Gonzalez C.
Human EWS-FLI protein levels and neomorphic functions show a complex, function-specific dose-response relationship in Drosophila.
OPEN BIOLOGY . 14(7): 240043-240043.
-
Caballero R, Pasten A, Giménez C, Raquel Rodriguez Baladon, Carmona-Jiménez RM, Mora J, Valls-Esteve A, Lustig P, Lombardini F, Balsells S and Krauel L.
Beyond Needles: Pioneering Pediatric Care with Virtual Reality (VR) for TIVAD Access in Oncology.
Cancers . 16(12): .
-
Sanchez-Guixe E, Muiños F, Pinheiro-Santin M, González-Huici V, Rodriguez-Hernandez CJ, Avgustinova A, Lavarino C, González- Pérez A, Mora J and López-Bigas N.
Origins of Second Malignancies in Children and Mutational Footprint of Chemotherapy in Normal Tissues
CANCER DISCOVERY . 14(6): 953-964. Nº de cites: 4
-
Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.
Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects
Frontiers in oncology . 14: 1380917-1380917.
-
Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy
Cancers . 16(9): . Nº de cites: 1
-
Pasten A, Salvador-Alarcon C, Mora J, Martín Gimenez MP, Carrasco-Torrents R and Krauel L.
Current Status of Fertility Preservation in Pediatric Oncology Patients.
CHILDREN-BASEL . 11(5): . Nº de cites: 1
-
Mora J, Modak S, Kinsey J, Ragsdale CE and Lazarus HM.
GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma
INTERNATIONAL JOURNAL OF CANCER . 154(8): 1340-1364. Nº de cites: 6
-
Llurba E, Fàtima Crispi Brillas, Crovetto F, Youssef L, Delgado JL, Puig I, Mora J, Krofta L, Mackova K, Martinez-Varea A, Tubau A, Ruiz-Llobet A, Paya A, Prat M, Chantraine F, Comas C, Kajdy A, Lopez-Tinajero MF, Figueras-Retuerta F and Gratacós E.
Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study.
BMJ Open . 14(3): . Nº de cites: 1
-
Villasante A, Corominas J, Alcon C, Garcia-Lizarribar A, Mora J, Lopez-Fanarraga M and Samitier J.
Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model
Cancers . 16(5): . Nº de cites: 1